NCT04928066View on ClinicalTrials.gov

The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

July 30, 2023

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Iguratimod

Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

DRUG

Tofacitinib

Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

DRUG

Pred

Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.

Trial Locations (1)

250012

Qilu Hospital, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER

NCT04928066 - The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA | Biotech Hunter | Biotech Hunter